Lexaria Bioscience (LEXX) has released an update.
Lexaria Bioscience Corp. reports rapid growth in the GLP-1 market, with significant dominance by two drugs from Novo Nordisk and Eli Lilly, and anticipates that its DehydraTECH system could lead in oral drug delivery. The GLP-1 sector has expanded to $11.04 billion in Q2 2024 from under $4 billion in 2020, with oral tablet forms poised to capture more market share. Analysts are closely monitoring the sector’s evolution, with various projections estimating billions in revenue growth over the next decade.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.
